CoChat

The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay

Open access
Xia, Jie, Hu, Huabin, Xue, Wenjie, Wang, Xiang Simon, Wu, Song · 2018 · Journal of Enzyme Inhibition and Medicinal Chemistry

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

Histone deacetylase 3 (HDAC3) is a potential target for the treatment of human diseases such as cancers, diabetes, chronic inflammation and neurodegenerative diseases. Previously, we proposed a virtual screening (VS) pipeline named “Hypo1_FRED_SAHA-3” for the discovery of HDAC3 inhibitors (HDAC3Is) and had thoroughly validated it by theoretical calculations. In this study, we attempted to explore its practical utility in a large-scale VS campaign. To this end, we used the VS pipeline to hierarchically screen the Specs chemical library. In order to facilitate compound cherry-picking, we then developed a knowledge-based pose filter (PF) by using our in-house quantitative structure activity relationship- (QSAR-) modelling approach and coupled it with FRED and Autodock Vina. Afterward, we purchased and tested 11 diverse compounds for their HDAC3 inhibitory activity in vitro. The bioassay has identified compound 2 (Specs ID: AN-979/41971160) as a HDAC3I (IC50 = 6.1 μM), which proved the efficacy of our workflow. As a medicinal chemistry study, we performed a follow-up substructure search and identified two more hit compounds of the same chemical type, i.e. 2–1 (AQ-390/42122119, IC50 = 1.3 μM) and 2–2 (AN-329/43450111, IC50 = 12.5 μM). Based on the chemical structures and activities, we have demonstrated the essential role of the capping group in maintaining the activity for this class of HDAC3Is. In addition, we tested the hit compounds for their in vitro activities on other HDACs, including HDAC1, HDAC2, HDAC8, HDAC4 and HDAC6. We have identified these compounds are HDAC1/2/3 selective inhibitors, of which compound 2 show the best selectivity profile. Taken together, the present study is an experimental validation and an update to our earlier VS strategy. The identified hits could be used as starting structures for the development of highly potent and selective HDAC3Is.

Overview

Integrity signals

Registry

Crossref · 10.1080/14756366.2018.1437156

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Figures

Graphical abstract
Graphical abstract CC BY · PubMed Central
Figure 1. The reported HDAC3-selective inhibitors for the treatment of a range of diseases.
Figure 1. The reported HDAC3-selective inhibitors for the treatment of a range of diseases.CC BY · PubMed Central
Figure 2. The workflow for the discovery of novel HDAC3 inhibitors. The number refers to the amount of chemical entities that entered the next component of the workflow.
Figure 2. The workflow for the discovery of novel HDAC3 inhibitors. The number refers to the amount of chemical entities that entered the next component of the workflow.CC BY · PubMed Central
Figure 3. Dose response curves of 2 (A) and its derivatives from substructure search (i.e. 2–1 ∼ 2–5, B). The dose response curves of the positive drug (i.e. SAHA) in two rounds of bioassays are also shown.
Figure 3. Dose response curves of 2 (A) and its derivatives from substructure search (i.e. 2–1 ∼ 2–5, B). The dose response curves of the positive drug (i.e. SAHA) in two rounds of bioassays are also shown.CC BY · PubMed Central
Figure 4. The modes of compound 2 (A), 2–1 (B) and 2–2 (C) bound to HDAC3, predicted by FRED. Colour codes: light blue, HDAC3; green, hit compounds; blue sphere, zinc ion.
Figure 4. The modes of compound 2 (A), 2–1 (B) and 2–2 (C) bound to HDAC3, predicted by FRED. Colour codes: light blue, HDAC3; green, hit compounds; blue sphere, zinc ion.CC BY · PubMed Central

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 52 references

Cited by

See all 24

Metadata

Authors
Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Howard University (US)
Corresponding author
  • Xia, Jie
  • Wu, Song
Venue
Journal of Enzyme Inhibition and Medicinal Chemistry
Published
2018-01-01
Volume
33
Issue
1
Pages
525-535
ISSN
  • 1475-6366 (ISSN-L)
  • 1475-6374
OpenAlex
W2793548260
Cited by
24
References
52
Citations by year
2026: 1 · 2025: 3 · 2024: 5 · 2023: 5 · 2022: 1 · 2021: 3 · 2020: 2 · 2019: 4
FWCI
0.80
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Journal of Enzyme Inhibition and Medicinal Chemistry (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Fundamental Research Funds for the Central Universities (2016ZX350036)
  • National Natural Science Foundation of China (81603027)
  • CAMS Innovation Fund for Medical Sciences (2017-I2M-2-004)
  • State Administration of Foreign Experts Affairs P.R. China (T2017069)
  • District of Columbia Developmental Center for AIDS Research (P30AI087714)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
HDAC3 inhibitors, HDAC3, virtual screening, QSAR models, FRED, AutoDock Vina, capping groups, substructure search, hit identification
MeSH terms
Histone Deacetylase 3, Biological Assay, Dose-Response Relationship, Drug, Histone Deacetylases, Humans, Models, Molecular, Molecular Structure, Quantitative Structure-Activity Relationship, Drug Discovery, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. https://app.cochat.ai/papers/10.1080/14756366.2018.1437156
The paper
Xia, J., Hu, H., Xue, W., Wang, X. S., & Wu, S. (2018). The discovery of novel HDAC3 inhibitors via virtual screening and in vitro bioassay. Journal of Enzyme Inhibition and Medicinal Chemistry. https://doi.org/10.1080/14756366.2018.1437156

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.